{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:35:12Z","timestamp":1769117712959,"version":"3.49.0"},"reference-count":52,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:p>Hypertension affects &amp;gt;40% of the US population and is a major contributor to cardiovascular-related morbidity and mortality. Although less common among children and adolescents, hypertension affects 1% to 5% of all youth. The 2017 Clinical Practice Guideline for the Diagnosis and Management of High Blood Pressure in Children and Adolescents provided updates and strategies regarding the diagnosis and management of hypertension in youth. Despite this important information, many gaps in knowledge remain, such as the etiology, prevalence, and trends of hypertension; the utility and practicality of ambulatory blood pressure monitoring; practical goals for lifestyle modification that are generalizable; the long-term end-organ impacts of hypertension in youth; and the long-term safety and efficacy of antihypertensive therapy in youth. The Eunice Kennedy Shriver National Institute of Child Health and Human Development, in collaboration with the National Heart, Lung, and Blood Institute and the US Food and Drug Administration, sponsored a workshop of experts to discuss the current state of childhood primary hypertension. We highlight the results of that workshop and aim to (1) provide an overview of current practices related to the diagnosis, management, and treatment of primary pediatric hypertension; (2) identify related research gaps; and (3) propose ways to address existing research gaps.<\/jats:p>","DOI":"10.1542\/peds.2018-3517","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T12:25:11Z","timestamp":1556195111000},"source":"Crossref","is-referenced-by-count":27,"title":["Research Gaps in Primary Pediatric Hypertension"],"prefix":"10.1542","volume":"143","author":[{"given":"Perdita","family":"Taylor-Zapata","sequence":"first","affiliation":[{"name":"Obstetric and Pediatric Pharmacology and Therapeutics Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carissa M.","family":"Baker-Smith","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Maryland, Baltimore, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Burckart","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Immediate Office of the Commissioner, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen R.","family":"Daniels","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Cardiology, School of Medicine, University of Colorado, Aurora, Colorado;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Flynn","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Washington, Seattle, Washington;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Giacoia","sequence":"additional","affiliation":[{"name":"Obstetric and Pediatric Pharmacology and Therapeutics Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionna","family":"Green","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Pediatric Obesity Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Khurana","sequence":"additional","affiliation":[{"name":"Division of Pediatric and Maternal Health, Office of New Drugs,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Duke University, Durham, North Carolina; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Pratt","sequence":"additional","affiliation":[{"name":"Clinical Applications and Prevention Branch, National Heart, Lung, and Blood Institute, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine M.","family":"Urbina","sequence":"additional","affiliation":[{"name":"Heart Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Zajicek","sequence":"additional","affiliation":[{"name":"Office of Clinical Research Training and Medical Education, National Institutes of Health, Bethesda, Maryland;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"2021121013182135500_B1","unstructured":"US Preventive Services Task Force. Final recommendation statement: blood pressure in children and adolescents (hypertension): screening. 2016. Available at: https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/blood-pressure-in-children-and-adolescents-hypertension-screening. Accessed October 13, 2018"},{"key":"2021121013182135500_B2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jpeds.2016.08.076","article-title":"Neurocognitive function in children with primary hypertension.","volume":"180","author":"Lande","year":"2017","journal-title":"J Pediatr"},{"issue":"1","key":"2021121013182135500_B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MBP.0000000000000219","article-title":"Blood pressure and left ventricular mass index in healthy adolescents.","volume":"22","author":"Daimee","year":"2017","journal-title":"Blood Press Monit"},{"issue":"1","key":"2021121013182135500_B4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","article-title":"Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group.","volume":"340","author":"O\u2019Leary","year":"1999","journal-title":"N Engl J Med"},{"issue":"5","key":"2021121013182135500_B5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1751-7176.2011.00471.x","article-title":"Cardiac and vascular consequences of pre-hypertension in youth.","volume":"13","author":"Urbina","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"19","key":"2021121013182135500_B6","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1161\/01.CIR.97.19.1907","article-title":"Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension.","volume":"97","author":"Daniels","year":"1998","journal-title":"Circulation"},{"issue":"5","key":"2021121013182135500_B7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/0735-1097(94)00540-7","article-title":"Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk.","volume":"25","author":"de Simone","year":"1995","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2021121013182135500_B8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/0895-7061(95)00116-7","article-title":"Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study.","volume":"8","author":"Bao","year":"1995","journal-title":"Am J Hypertens"},{"issue":"3","key":"2021121013182135500_B9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1542\/peds.2012-3523","article-title":"Screening for hypertension in children and adolescents to prevent cardiovascular disease.","volume":"131","author":"Thompson","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"2021121013182135500_B10","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/HYPERTENSIONAHA.115.05831","article-title":"Childhood to early-midlife systolic blood pressure trajectories: early-life predictors, effect modifiers, and adult cardiovascular outcomes.","volume":"66","author":"Theodore","year":"2015","journal-title":"Hypertension"},{"issue":"6","key":"2021121013182135500_B11","doi-asserted-by":"crossref","first-page":"e20162195","DOI":"10.1542\/peds.2016-2195","article-title":"Diagnosis and medication treatment of pediatric hypertension: a retrospective cohort study.","volume":"138","author":"Kaelber","year":"2016","journal-title":"Pediatrics"},{"key":"2021121013182135500_B12","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.114.S2.555","article-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","journal-title":"Pediatrics"},{"issue":"8","key":"2021121013182135500_B13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jama.298.8.874","article-title":"Underdiagnosis of hypertension in children and adolescents.","volume":"298","author":"Hansen","year":"2007","journal-title":"JAMA"},{"key":"2021121013182135500_B14","first-page":"797","article-title":"Report of the Task Force on Blood Pressure Control in Children.","volume":"59","author":"National Heart, Lung, and Blood Institute","year":"1977","journal-title":"Pediatrics"},{"issue":"4","key":"2021121013182135500_B15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/HYPERTENSIONAHA.117.10050","article-title":"New clinical practice guideline for the management of high blood pressure in children and adolescents.","volume":"70","author":"Flynn","year":"2017","journal-title":"Hypertension"},{"issue":"3","key":"2021121013182135500_B16","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents.","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"key":"2021121013182135500_B17","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report.","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents","year":"2011","journal-title":"Pediatrics"},{"issue":"6","key":"2021121013182135500_B18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jpeds.2007.01.052","article-title":"Prevalence of hypertension and pre-hypertension among adolescents.","volume":"150","author":"McNiece","year":"2007","journal-title":"J Pediatr"},{"issue":"11","key":"2021121013182135500_B19","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1097\/HJH.0b013e3282ef48b2","article-title":"Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight.","volume":"25","author":"Chiolero","year":"2007","journal-title":"J Hypertens"},{"issue":"3","key":"2021121013182135500_B20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2010.03.032","article-title":"Prevalence and incidence of hypertension in adolescent girls.","volume":"157","author":"Obarzanek","year":"2010","journal-title":"J Pediatr"},{"issue":"2","key":"2021121013182135500_B21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jada.2007.10.049","article-title":"Metabolic syndrome and its association with diet and physical activity in US adolescents.","volume":"108","author":"Pan","year":"2008","journal-title":"J Am Diet Assoc"},{"issue":"14","key":"2021121013182135500_B22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa1502821","article-title":"Cardiometabolic risks and severity of obesity in children and young adults.","volume":"373","author":"Skinner","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2021121013182135500_B23","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1542\/peds.2006-2136","article-title":"Has blood pressure increased in children in response to the obesity epidemic?","volume":"119","author":"Chiolero","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"2021121013182135500_B24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/HYPERTENSIONAHA.117.09649","article-title":"Is blood pressure improving in children with chronic kidney disease? A period analysis.","volume":"71","author":"Barletta","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"2021121013182135500_B25","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.11401017","article-title":"Prevalence of hypertension in children with early-stage ADPKD.","volume":"13","author":"Massella","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2021121013182135500_B26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/HYPERTENSIONAHA.111.00831","article-title":"Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008.","volume":"62","author":"Rosner","year":"2013","journal-title":"Hypertension"},{"issue":"2","key":"2021121013182135500_B27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00467-006-0311-3","article-title":"Blood pressure in non-critically ill preterm and full-term neonates.","volume":"22","author":"Pejovic","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"2021121013182135500_B28","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00467-007-0561-8","article-title":"Blood pressure in the first year of life in healthy infants born at term.","volume":"22","author":"Kent","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2021121013182135500_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.79.1.1","article-title":"Report of the second Task Force on Blood Pressure Control in Children\u20131987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland.","volume":"79","author":"National Heart, Lung, and Blood Institute","year":"1987","journal-title":"Pediatrics"},{"issue":"4","key":"2021121013182135500_B30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/HYPERTENSIONAHA.107.104950","article-title":"Safety of placebo controls in pediatric hypertension trials.","volume":"51","author":"Smith","year":"2008","journal-title":"Hypertension"},{"issue":"2","key":"2021121013182135500_B31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpeds.2006.09.034","article-title":"Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience.","volume":"150","author":"Batisky","year":"2007","journal-title":"J Pediatr"},{"issue":"2","key":"2021121013182135500_B32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0091270002239820","article-title":"Pharmacokinetics of quinapril in children: assessment during substitution for chronic angiotensin-converting enzyme inhibitor treatment.","volume":"43","author":"Blumer","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2021121013182135500_B33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/HYPERTENSIONAHA.108.111054","article-title":"Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years.","volume":"52","author":"Flynn","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"2021121013182135500_B34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jpeds.2004.04.009","article-title":"A randomized, placebo-controlled trial of amlodipine in children with hypertension.","volume":"145","author":"Flynn","year":"2004","journal-title":"J Pediatr"},{"issue":"3","key":"2021121013182135500_B35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/01.HYP.0000138069.68413.f0","article-title":"Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?","volume":"44","author":"Li","year":"2004","journal-title":"Hypertension"},{"issue":"2","key":"2021121013182135500_B36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jpeds.2010.02.042","article-title":"The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.","volume":"157","author":"Li","year":"2010","journal-title":"J Pediatr"},{"issue":"7","key":"2021121013182135500_B37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/00912700122010645","article-title":"The pharmacokinetics of irbesartan in hypertensive children and adolescents.","volume":"41","author":"Sakarcan","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"2 pt 1","key":"2021121013182135500_B38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amjhyper.2004.09.009","article-title":"A double-blind, dose-response study of losartan in hypertensive children [published correction appears in Am J Hypertens. 2006;19(6):658].","volume":"18","author":"Shahinfar","year":"2005","journal-title":"Am J Hypertens"},{"issue":"10","key":"2021121013182135500_B39","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0895-7061(03)00900-2","article-title":"A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension.","volume":"16","author":"Soffer","year":"2003","journal-title":"Am J Hypertens"},{"issue":"5","key":"2021121013182135500_B40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00467-002-0851-0","article-title":"Beta-blocker\/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial.","volume":"17","author":"Sorof","year":"2002","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2021121013182135500_B41","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s00467-003-1134-0","article-title":"Clinical trial of extended-release felodipine in pediatric essential hypertension.","volume":"18","author":"Trachtman","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"2021121013182135500_B42","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1751-7176.2008.00022.x","article-title":"Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.","volume":"10","author":"Trachtman","year":"2008","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"8","key":"2021121013182135500_B43","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/009127002401102786","article-title":"A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension.","volume":"42","author":"Wells","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"2021121013182135500_B44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1161\/HYPERTENSIONAHA.109.147702","article-title":"A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.","volume":"55","author":"Hazan","year":"2010","journal-title":"Hypertension"},{"issue":"10","key":"2021121013182135500_B45","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1751-7176.2011.00502.x","article-title":"The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.","volume":"13","author":"Meyers","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"12","key":"2021121013182135500_B46","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1097\/HJH.0b013e32834c625c","article-title":"Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study.","volume":"29","author":"Schaefer","year":"2011","journal-title":"J Hypertens"},{"issue":"5","key":"2021121013182135500_B47","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/HJH.0b013e328336b86b","article-title":"Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.","volume":"28","author":"Schaefer","year":"2010","journal-title":"J Hypertens"},{"issue":"5","key":"2021121013182135500_B48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1751-7176.2011.00432.x","article-title":"Effectiveness and safety of valsartan in children aged 6 to 16\u2003years with hypertension.","volume":"13","author":"Wells","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10","key":"2021121013182135500_B49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/0009922810363609","article-title":"Safety, efficacy, and pharmacokinetics of telmisartan in pediatric patients with hypertension.","volume":"49","author":"Wells","year":"2010","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"2021121013182135500_B50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/apa.14110","article-title":"High blood pressure in the young: why should we care?","volume":"107","author":"Flynn","year":"2018","journal-title":"Acta Paediatr"},{"issue":"3","key":"2021121013182135500_B51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1161\/HYPERTENSIONAHA.118.11434","article-title":"SHIP-AHOY (Study of High Blood Pressure in Pediatrics: Adult Hypertension Onset in Youth).","volume":"72","author":"Mendiz\u00e1bal","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"2021121013182135500_B52","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1067\/S0022-3476(03)00412-8","article-title":"Elevated blood pressure and decreased cognitive function among school-age children and adolescents in the United States.","volume":"143","author":"Lande","year":"2003","journal-title":"J Pediatr"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-3517\/1076991\/peds_20183517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-3517\/1076991\/peds_20183517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T02:22:23Z","timestamp":1639189343000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/143\/5\/e20183517\/37156\/Research-Gaps-in-Primary-Pediatric-Hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,1]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-3517","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"article-number":"e20183517"}}